ArticleNature2023
Non-cell-autonomous cancer progression from chromosomal instability.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 220 papers.
0numbers the graph read from it
0cells of the map it votes in
220citing papers in PubMed
41.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
220 citing papers in PubMed, 255 citations in OpenAlex.
- Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.Nature communications · 2026Trial
- Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.Nature medicine · 2025Trial
- Article
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- The cGAS-STING/MITA pathway in innate antiviral immunity and beyond.Cell insight · 2026Review
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- TALAVE in Breast Cancer:bioRxiv : the preprint server for biology · 2026Article
- Chromosomal instability in cancer: sources, consequences and new therapeutic opportunities.Signal transduction and targeted therapy · 2026Review
- Melanoma evolution in the lymph node shapes systemic outcomes.bioRxiv : the preprint server for biology · 2026Article
- A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer.Cancer cell · 2026Article
- The DNA damage response and cancer immunotherapy.Nature reviews. Cancer · 2026Review
- Histone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response.Nature communications · 2026Article
- Redox regulation of neuroinflammatory pathways contributes to damage in Alzheimer's disease brain.Cell chemical biology · 2026Article
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
- The cGAS/STING pathway in cancer: translating innate DNA sensing into therapeutic potential.The Journal of clinical investigation · 2026Review
- YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- A tumour-host feed-forward loop contributes to the growth of chromosomal instability-induced tumours.EMBO reports · 2026Article
- Article
- Microtubule-Associated Proteins: From Dynamic Regulation of Microtubules to Cellular Architecture.Cells · 2026Review
- BAP1 deficiency-induced SKA3 promotes clear cell renal cell carcinoma malignant progression by regulating chromosomal instability.Cell death & disease · 2026Article
160 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
25 authors at 6 institutions in 2 countries.
Jun Li *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6836-2716
Melissa J Hubisz *Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9561-6830
Ethan M Earlie *Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-3039-9692
Mercedes A Duran *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0002-9974-4095
Christy HongHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Austin A VarelaDepartment of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9068-7605
Emanuele LetteraHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matthew DeyellDepartment of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine, New York, NY, USA.ORCID 0009-0009-6543-1171
Bernardo TavoraVolastra Therapeutics Inc., New York, NY, USA.
Jonathan J HavelVolastra Therapeutics Inc., New York, NY, USA.ORCID 0000-0003-0951-510X
Su M PhyuDepartment of Oncology, Medical Sciences Division, University of Oxford, Oxford, UK.ORCID 0000-0003-1775-6966
Amit Dipak AminColumbia Center for Translational Immunology, New York, NY, USA.ORCID 0000-0002-2613-2082
Karolina BudreDepartment of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine, New York, NY, USA.
Erina KamiyaDepartment of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-9048-5125
Julie-Ann CavalloHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christopher GarrisDepartment of Pathology, Harvard Medical School, Boston, MA, USA.
Simon PowellDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8183-4765
Jorge S Reis-FilhoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2969-3173
Hannah WenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sarah BettigoleVolastra Therapeutics Inc., New York, NY, USA.
Atif J KhanDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin IzarColumbia Center for Translational Immunology, New York, NY, USA.ORCID 0000-0003-2379-6702
Eileen E ParkesDepartment of Oncology, Medical Sciences Division, University of Oxford, Oxford, UK.
Ashley M Laughney *Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine, New York, NY, USA. ashley.laughney@gmail.com.ORCID 0000-0001-9435-953X
Samuel F Bakhoum *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. samuel.bakhoum@gmail.com.ORCID 0000-0002-4779-8422
Memorial Sloan Kettering Cancer Center · USCornell University · USAcorda Therapeutics (United States) · USColumbia University Irving Medical Center · USUniversity of Oxford · GBHarvard University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3MTri-Institutional PhD Program in Computational Biology & MedicineT32GM132083 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Doron Betel, Iman Hajirasouliha · 2020 to 2026
$3.6MEnvironmental Regulation of Cancer Stem Cell Plasticity in MetastasisU01CA210152 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAHANN, JOERG, LUKER, GARY D · 2017 to 2021
$3.6MProbing cytosolic nucleic acid sensing pathways in cancerR01CA256188 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LAUGHNEY, ASHLEY MARIE · 2021 to 2025
$3.5MDissecting the impact of tumor-intrinsic chromosomal instability on the cancer ecosystemR01CA280572 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOHN BLENIS, Ashley Marie Laughney · 2023 to 2026
$2.9MMulti-cellular interactions defining the human brain metastatic nicheR01CA280414 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Benjamin Izar, Ashley Marie Laughney · 2023 to 2026
$2.8MMechanisms of liver metastasis and associated resistance to immunotherapyR37CA258829 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Benjamin Izar · 2021 to 2026
$2.6MThe role of chromosomal instability in tumor evolutionDP5OD026395 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI BAKHOUM, SAMUEL F · 2018 to 2022
$2.2MThe role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapyR01CA266446 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FRANGIEH, CHRISTOPHER · 2022 to 2025
$2.0MDissecting drug resistance in serial uveal melanoma biopsies using integrated, multi-modal single-cell profiling and novel machine learning tools.R21CA263381 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IZAR, BENJAMIN · 2021 to 2022
$412kRole of the smooth muscle layer in bladder cancer biology and progression: a systems and experimental approachR21CA266660 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LAUGHNEY, ASHLEY MARIE, REAL, FRANCISCO XAVIER · 2022 to 2022
$374kNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA256188NCI NIH HHS R01 CA266446NCI NIH HHS R01 CA280414NCI NIH HHS R01 CA280572NCI NIH HHS R21 CA263381NCI NIH HHS R21 CA266660NCI NIH HHS R37 CA258829NCI NIH HHS U01 CA210152NIGMS NIH HHS T32 GM132083NIH HHS DP5 OD026395Wellcome Trust
Abstract
Chromosomal instability (CIN) is a driver of cancer metastasis
Indexed as
Chromosomal InstabilityDisease ProgressionNeoplasmsBenchmarkingCell CommunicationColorectal NeoplasmsCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseEndoplasmic Reticulum StressHumansInterferon Type IMelanomaNeoplasm MetastasisSignal TransductionSTING ProteinTriple Negative Breast NeoplasmsTumor MicroenvironmentcGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseInterferon Type ISTING1 protein, humanSTING Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.